CTT Pharma Progresses in NSF Grant for Nicotine Strips

CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) has advanced past the initial round in its application for a National Science Foundation (NSF) grant. The company seeks funding for its patented fast-dissolving nicotine strips. This NSF program is competitive, evaluating over 12,000 applicants annually that present innovations with societal benefits. CTT remains among a few thousand candidates proceeding in this process, with a decision expected by late April.

The World Health Organization highlights the tobacco epidemic's severe impact, causing over 8 million deaths globally each year. In the United States, the CDC reports that cigarette smoking accounts for more than 480,000 deaths annually. CTT's technology could address this by providing a new product aimed at reducing nicotine-related harm.

CEO Ryan Khouri emphasizes the achievement of passing the first round, noting the NSF's recognition of the technology's potential in the tobacco sector. Additionally, the company has enlisted an expert to support their NSF grant efforts.